Constituent policy

Electronic Nicotine Delivery Systems: Updated Statement from the American Association for Cancer Research and the American Society of Clinical Oncology | Clinical cancer research

RS Herbst Reports Cybrexa Therapeutics Personal Fee, eFFECTOR Therapeutics, Inc. Personal Fee, Eli Lilly and Company Personal Fee, EMD Serono Personal Fee, Genentech Personal Fee, Gilead Personal Fee , Janssen personal fee, Merck and Company personal fee, Mirati Therapeutics personal fee, NextCure personal fee, Novartis personal fee, Ocean Biomedical, Inc personal fee, Oncocyte Corp personal fee, Oncternal Therapeutics, Pfizer Personal Fee, Regeneron Pharmaceuticals Personal Fee, Revelar Biotherapeutics, Inc Personal Fee, Ribbon Therapeutics, Inc Personal Fee, Roche Personal Fee, Sanofi Personal Fee, Xencor, Inc Personal Fee, Other Support from the American Association for Cancer Research, other support from the International Association for Cancer Research, other support from the Society for Immunotherapy of Cancer, other support from the Southwest Oncology Group, other support from Merck and Company, and other support from Eli Lilly and Company outside of the submitted work. Mr. Giuliani reports further support from AstraZeneca, further support from Bristol Myers Squibb, and further support from the International Journal of Radiation Oncology, Biology and Physics outside of the submitted work. BA Toll reports grants from the National Cancer Institute and personal costs for expert testimony outside of submitted work. GW Warren reports grants and other support from the National Cancer Institute, Agency for Healthcare Research and Quality, Canadian Partnership Against Cancer outside of submitted work. No disclosures were reported by the other authors.